Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:3823444rdf:typepubmed:Citationlld:pubmed
pubmed-article:3823444lifeskim:mentionsumls-concept:C0373440lld:lifeskim
pubmed-article:3823444lifeskim:mentionsumls-concept:C0007818lld:lifeskim
pubmed-article:3823444lifeskim:mentionsumls-concept:C0680730lld:lifeskim
pubmed-article:3823444lifeskim:mentionsumls-concept:C0559546lld:lifeskim
pubmed-article:3823444lifeskim:mentionsumls-concept:C0428714lld:lifeskim
pubmed-article:3823444lifeskim:mentionsumls-concept:C1148554lld:lifeskim
pubmed-article:3823444pubmed:issue1lld:pubmed
pubmed-article:3823444pubmed:dateCreated1987-4-15lld:pubmed
pubmed-article:3823444pubmed:abstractTextFourteen institutions performed 1,830 computed tomographic (CT) cerebral blood flow (CBF) examinations with 32% inhaled stable xenon. Respiratory rate delay greater than 10 seconds occurred in 3.6% of patients, with 83% of the delays lasting 10-15 seconds. There was no incident of prolonged respiratory difficulty. Headache (0.4%), seizures (0.2%), nausea and vomiting (0.2%), and change in neurologic status (0.1%) were uncommon, and there were no transient ischemic attacks. The CT CBF method with 32% inhaled stable xenon is thus associated with an acceptably low incidence of adverse reactions.lld:pubmed
pubmed-article:3823444pubmed:languageenglld:pubmed
pubmed-article:3823444pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823444pubmed:citationSubsetAIMlld:pubmed
pubmed-article:3823444pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:3823444pubmed:statusMEDLINElld:pubmed
pubmed-article:3823444pubmed:monthAprlld:pubmed
pubmed-article:3823444pubmed:issn0033-8419lld:pubmed
pubmed-article:3823444pubmed:authorpubmed-author:LatchawR ERElld:pubmed
pubmed-article:3823444pubmed:authorpubmed-author:GuyKKlld:pubmed
pubmed-article:3823444pubmed:authorpubmed-author:YonasHHlld:pubmed
pubmed-article:3823444pubmed:authorpubmed-author:PenthenyS LSLlld:pubmed
pubmed-article:3823444pubmed:issnTypePrintlld:pubmed
pubmed-article:3823444pubmed:volume163lld:pubmed
pubmed-article:3823444pubmed:ownerNLMlld:pubmed
pubmed-article:3823444pubmed:authorsCompleteYlld:pubmed
pubmed-article:3823444pubmed:pagination251-4lld:pubmed
pubmed-article:3823444pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:meshHeadingpubmed-meshheading:3823444-...lld:pubmed
pubmed-article:3823444pubmed:year1987lld:pubmed
pubmed-article:3823444pubmed:articleTitleAdverse reactions to xenon-enhanced CT cerebral blood flow determination.lld:pubmed
pubmed-article:3823444pubmed:publicationTypeJournal Articlelld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3823444lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:3823444lld:pubmed